There is much debate about the prices of brand name drugs in the U.S, when compared to prices in other developed countries. Medicinal products in the U.S are typically much higher in the U.S than in other countries. The pharma industry has always argued that it’s not possible to get the whole picture, by looking at the U.S list prices that exclude discount struck between the drug companies and insurances in private negotiations.
The industry has always stated that the price hikes are a means to fund research and develop new drugs, however with a close look a company financials, the RD is often lower than company overhead, including marketing cost. A Wall Street Journal report should say that drug price increase typically outpaces inflation, even as demand for the drug fades.
According to Credit Suisse report, drug price increases were a “key driver” in profit growth. The increase in drug price correlated directly with increased profit margins. Leading many people to believe that U.S consumer pay to subside marketing activities and profits more than financing new-drug research.
Based on a report from Bloomberg, prices, even after the discounts, prices are higher in the U.S than abroad. They examed eight of the top selling drugs, examed still cost more in the U.S tan most other countries.
According to Bloomberg research, they estimated the actual cost that pharmaceutical companies are based on a sample of top-selling drugs.
SSR Health and investment research firm used the prescription drug data and U.S list prices to determine the drugs sales in the country before discounts. To determine the SSR discount health subtracted the actual U.S sales reported by the companies. Bloomberg compared the discounted monthly prices with list prices from 14 different countries, using local data from IHS a data analysis consulting firm, and other sources.
According to Express Scripts Holding, the largest U.S prescription-drug benefits, 在這種情況下, Americans are subsidizing the drug development cost for the entire world. 然而, pharmaceutical companies view it differently. According to the pharmaceutical industry, the whole health-care system is more expensive. The industry claims the difference in parties in the U.S compared to other countries are overstood because the discounts drug manufacturers give to various insurance payers are not included.
It is true that that insurance and pharmacy benefits managers do receive significant discounts from the listed prices. Sometimes the discount can be 50 percent or more.
Over the eight drugs analyzed, seven of them cost more in the U.S after esteemed discount tan in most other high-income countries. Discount for eight drugs, the cancer treatment Gleevec, could not be obtained. The list price in the U.S is much higher than the rest of the world.
The list price of Merck’s diabetes pill Januvia is cut in half on average by estimated discount. Even with the discounts, Merck gets more than double the price in the U.S. for a monthly supply of the same drug as in Canada, the next most expensive place to buy it, Bloomberg found. Humira, AbbVie Inc.’s top-selling rheumatoid arthritis treatment, is priced at $2,500 a month in the U.S. after discounts, v.s $1,750 in Germany. In other nations, the drug’s price drops even lower.
According to Merck, they don’t disclose discounts for competitive reasons. Drug sales go through differently channels and levels of prices and rebates. Roche Holding AG’s Herceptin breast cancer do have 15 percent rebates, however still cost 85% more in the U.S than other high-income countries and one-third more than in Saudia Arabia, the second highest price country, after the U.S According to Roche they strive to ensure a balance between patient access and necessary medicine breakthroughs.
The U.S drug makers set their prices and raise them over time. Medicare is the largest U.S buyer of medicine. Medicare prohibited from negotiating priced directly with drug manufacturers. 私人保險機構和福利經理可以創建與製藥公司的回扣交易. 然而, 這些合同的細節沒有公開披露. 在歐洲藥品價格常常由政府衛生實體集, 隨著時間的推移下降，因為國家要求額外降價. 在美國，價格上浮, 而不是在歐洲下降.
按照Phamactual行業, 藥品費用僅佔 12-14 中美支出的百分之所以它是不公平的挑選出來作為一個成本動因. 該PhRMA的聲稱，中美自由市場體系的好處，包括更便宜的仿製藥和新的治療方法更快地訪問.
即使有顯著折扣, 在美國和其他國家之間的價格差異比其他國家更, 之後 60% 折扣AstraXenca仍然收取兩倍的Crestor的膽固醇藥片在中美VS. 價格在德國. 在其他國家, 價格更低, 根據一個IHS分析.
Gilead公司表示，它的定價是根據國家’ 經濟和健康的背景, 與大多數國家的政府進行談判是保密.
SSR健康無法確定該藥折扣, 諾華的藥品白血病. 仍然, IHS數據的分析發現，中美. 標價為藥物超過3倍，諾華獲取其他高收入國家的利率. 諾華公司稱它提供回扣的格列衛, and that its rates range between countries for reasons including disparities in regulations, income levels, and type of health system.